Literature DB >> 1745051

p53 alterations in all stages of breast cancer.

A M Davidoff1, B J Kerns, J C Pence, J R Marks, J D Iglehart.   

Abstract

Overexpression of the nuclear phosphoprotein p53 is one of the most frequently detected abnormalities in human cancer and appears to be associated with mutation of the p53 gene. In this study of breast cancer, p53 overexpression was detected in two (15%) of 15 pure intraductal tumors, 73 (25%) of 291 primary invasive carcinomas, 13 (50%) of 26 lymph nodes containing metastatic breast cancer, and two of four established breast cancer cell lines. Sequence analysis of selected specimens confirmed that p53 overexpression was associated with mutation of the gene, while no mutations were detected in specimens without p53 overexpression. Thus, overexpression of p53 occurs in all stages of breast cancer and is consistently associated with the production of mutant proteins. Immunohistochemical analysis is a simple method which reliably predicts the presence of most p53 gene mutations in breast cancer specimens.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1745051     DOI: 10.1002/jso.2930480409

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  8 in total

1.  An inverse docking approach for identifying new potential anti-cancer targets.

Authors:  Sam Z Grinter; Yayun Liang; Sheng-You Huang; Salman M Hyder; Xiaoqin Zou
Journal:  J Mol Graph Model       Date:  2011-01-19       Impact factor: 2.518

Review 2.  The p53 tumor suppressor gene in breast cancer.

Authors:  R M Elledge; D C Allred
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

3.  TP53 alterations in atypical ductal hyperplasia and ductal carcinoma in situ of the breast.

Authors:  M Chitemerere; T I Andersen; R Holm; F Karlsen; A L Børresen; J M Nesland
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

Review 4.  Anti-invasion drugs.

Authors:  R B Dickson; M D Johnson; M Maemura; J Low
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

5.  Inhibition of the p38 kinase suppresses the proliferation of human ER-negative breast cancer cells.

Authors:  Lu Chen; Julie Ann Mayer; Tibor I Krisko; Corey W Speers; Tao Wang; Susan G Hilsenbeck; Powel H Brown
Journal:  Cancer Res       Date:  2009-11-17       Impact factor: 12.701

6.  Prognostic value of p53 in breast invasive ductal carcinoma: an immunohistochemical study on 942 cases.

Authors:  G MacGrogan; F Bonichon; I de Mascarel; M Trojani; M Durand; A Avril; J M Coindre
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872

7.  p53 immunohistochemical analysis in breast cancer with four monoclonal antibodies: comparison of staining and PCR-SSCP results.

Authors:  J Jacquemier; J P Molès; F Penault-Llorca; J Adélaide; M Torrente; P Viens; D Birnbaum; C Theillet
Journal:  Br J Cancer       Date:  1994-05       Impact factor: 7.640

8.  Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities.

Authors:  Swathi V Iyer; Alejandro Parrales; Priya Begani; Akshay Narkar; Amit S Adhikari; Luis A Martinez; Tomoo Iwakuma
Journal:  Oncotarget       Date:  2016-02-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.